Travere Therapeutics, Inc.

NASDAQ:TVTX

Biotechnology

Healthcare
$50.24 +1.20%

+$0.65 today

Market cap
$4.82B
Beta
1.14
P/E (TTM)
-235.0
EPS (TTM)
-$0.23
52W Low $13.97High $55.99

Volume 0.84M

Average 2.31M

TVTX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Travere Therapeutics, Inc.NASDAQ: TVTX

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA turns negative

Q3 FY2026 EBITDA was -$68.11M, compared with $44.25M a year earlier. Trailing-twelve-month EBITDA was -$106.58M.

Context

  • EBITDA amounted to 4.5% of revenue in FY2025, down 109.5 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 11 analysts of $31.09M (+39.9%) for the fiscal year ending Dec 2026, a slowdown from the +108.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$68.11M-137.9% QoQ
Last fiscal yearDec 2025
$22.22M+108.4% YoY
LTMSep 2026
-$106.58M-372.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-253.9%+11172.5%+11426.4 pp
1 year+108.4%+39.9%-68.4 pp
3-year CAGR—+230.0%—
5-year CAGR+117.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
22.22M USD
Year-over-year change
+108.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How TVTX compares with its peers on the latest reported figures

  • TVTX's LTM Sep 2026 EBITDA of -$106.58M is the 2nd highest of the 5 companies compared; the peer median is -$134.97M.
  • Its year-over-year change of -372.0% is the lowest of 5, against a peer median of -38.6%.
  • EBITDA amounts to 16.4% of revenue for TVTX, versus a peer median of 597.6%.
TVTX Competitors Peer median
EBITDA for TVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHARPharming Group N.V.LTM Mar 2026$39.48M +82.4%-1.9%10.7%
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$106.58M -372.0%—16.4%
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$119.51M -312.9%—597.6%
PROKProKidney Corp.LTM Mar 2026-$150.42M +6.1%—16919.8%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026-$349.54M -83.3%——
Peer median (excluding TVTX) -$134.97M-38.6%-1.9%597.6%

Competitors are the stored peer set for TVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue131.84M109.46M145.24M233.18M490.73M
Cost of Revenue3.82M4.42M11.45M7.74M10.34M
Gross Profit128.02M105.04M133.79M225.43M480.39M
Gross Margin97.1%96.0%92.1%96.7%97.9%
Research & Development201.16M227.33M244.99M282.7M206.01M
Selling, General & Admin126.28M197.52M265.54M264.12M337.2M
Operating Expenses327.44M424.85M521.93M549.26M543.21M
Depreciation & Amortization12.75M20.72M38.53M43.56M60.74M
EBITDA(184.46M)(299.42M)(326.25M)(265.77M)22.22M
EBITDA Margin-139.9%-273.5%-224.6%-114.0%4.5%
Operating Income(199.43M)(319.81M)(388.14M)(323.83M)(62.82M)
Operating Margin-151.3%-292.2%-267.2%-138.9%-12.8%
Interest Income1.99M6.28M21.77M17.82M12.72M
Interest Expense19.68M11.01M11.33M11.18M10.75M
Other Income / Expenses(17.46M)(11.34M)12.03M3.32M13.55M
Income Before Tax(216.88M)(331.16M)(376.11M)(320.51M)(49.27M)
Pre-Tax Margin-164.5%-302.5%-259.0%-137.5%-10.0%
Income Tax Expense409K313K223K120K988K
Net Income(180.09M)(278.48M)(111.4M)(321.55M)(25.55M)
Net Margin-136.6%-254.4%-76.7%-137.9%-5.2%
EPS (Basic)(3.01)(4.37)(1.50)(4.08)(0.56)
EPS (Diluted)(3.01)(4.37)(1.50)(4.08)(0.56)
Weighted Avg Shares59.83M63.76M74.27M78.89M89.21M
Weighted Avg Shares (Diluted)59.83M63.76M74.27M78.89M89.21M

Travere Therapeutics, Inc.

NASDAQ:TVTX

Intrinsic Alpha fair value

Locked

Current Price

$50.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.